Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

Exclusion Criteria25

• Subjects will be excluded from the study if one or more of the following statements are applicable to either eye:
• Additional interfering ocular conditions which would impact study results (e.g., ocular opacity and advanced cataract, uveitis, amblyopia)
• History or presence of glaucoma
• Ocular surgery, intravitreal or subretinal implantation of a medical device (within 6 months of screening)
• Mutations known to cause inherited retinal disease other than biallelic variants in the CNGA1 gene
• History of ocular infection with herpes simplex virus
• History of ocular malignancies
• History of disorders of the internal retina (e.g., retinal detachment)
• Patients with uncontrolled diabetes (HbA1c > 7%)
• Any other retinopathy due to other diseases - including, but not limited to arterial hypertension, previous vascular retinal occlusion, trauma or acquired inflammatory diseases, contraindication to pharmacological mydriasis (e.g., history of angle block glaucoma), diabetes (diabetic retinopathy including macular oedema)
• Absence of visual function on the contralateral eye
• Any damage to the optic nerve
• Individuals performing any other therapy for RP within 3 months before the study, such as - but not limited to - transcorneal electrostimulation
• Systemic conditions (e.g., autoimmune disorders) which may affect study participation or outcome measures
• History of immunodeficiency or other medical conditions which may increase the risk of VG901 administration
• Systemic illness (e.g., hepatitis or human immunodeficiency virus \[HIV\] infection) or medically relevant abnormal laboratory values (3 x upper limit of normal \[ULN\]) in blood analysis including renal and hepatic function
• Current, or recent, participation in other study/ or administration of investigational biologic agent within 3 months of Screening; Use of any investigational agent, or systemic corticosteroids, or other immunosuppressive drug(s) within 3 months before Screening
• History of allergy or sensitivity to any compound used in the study
• Contraindications to systemic immunosuppression
• Subjects with increased risk of bleeding (i.e., use of anticoagulants or anti-platelet agents within 7 days before VG901 administration and subjects with international normalized ratio > 2 or Quick < 50% or partial thromboplastin time > 50 seconds, thrombocytopenia, as well as any other known coagulopathy)
• Subject/partner of childbearing potential unwilling to use adequate contraception for the period between Screening and 30 days after treatment, defined as the period from Screening until 30 days after treatment (defined as administration of therapeutic to the eye)
• For females of childbearing potential, a positive pregnancy test at Screening or Baseline
• Females who are breastfeeding
• Previous receipt of any AAV gene therapy product
• Any condition which leads the investigator to believe that subject cannot comply with the protocol requirements or that may place the subject at an unacceptable risk from participating